Processa Pharmaceuticals (PCSA) EV to CFO (2014 - 2026)

Processa Pharmaceuticals (PCSA) has reported EV to CFO for 13 consecutive years, with 2.6 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EV to CFO fell 257.55% year-over-year to 2.6; the trailing twelve-month figure through Jun 2026 stood at 0.43 (down 224.8% YoY), and the FY2025 full-year result was 0.15, up 215.1% from the prior year.
• EV to CFO declined to 2.6 in Q2 2026 per PCSA's latest filing, from 1.41 in the prior quarter.
• Across five years, EV to CFO topped out at 1.65 in Q2 2025 and bottomed at 18.46 in Q1 2022.
• Historically, EV to CFO has averaged 2.95 across 5 years, with a median of 0.91 in 2025.
• The sharpest annual moves came in 2025 and 2026: EV to CFO surged 768.46% in 2025, then tumbled 515.81% in 2026.
• Over 5 years, EV to CFO stood at 4.46 in 2022, then soared by 58.71% to 1.84 in 2023, then jumped by 63.42% to 0.67 in 2024, then jumped by 190.44% to 0.61 in 2025, then tumbled by 527.05% to 2.6 in 2026.
• According to Business Quant data, EV to CFO over the past three periods registered 2.6, 1.41, and 0.61 for Q2 2026, Q1 2026, and Q4 2025 respectively.